Last updated: October 30, 2023
Sponsor: Nobles Medical Technologies II Inc
Overall Status: Suspended
Phase
N/A
Condition
Stroke
Thrombosis
Blood Clots
Treatment
Amplatzer PFO Occluder
NobleStitch™EL Suture Mediated Closure System
Clinical Study ID
NCT04339699
748824-0819
Ages 18-60 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for theduration of the study
- Male or female ages 18 - 60 years old
- A PFO and a Cryptogenic Stroke verified by a neurologist
- Stroke is defined as an acute focal neurological deficit, presumed to be due to focalischemia, and either:
- Symptoms persisting ≥24 hours, or
- Symptoms persisting <24 hours with Magnetic Resonance or CT findings of a new,neuroanatomical relevant infarct
- Cryptogenic stroke was defined as a stroke of unknown cause
- Prolonged cardiac rhythm monitoring (recommended 30 days and not less than 24 hoursrequired)
- Intra and extracranial artery imaging: Magnetic Resonance Angiography, CT angiography,or contrast angiography, or contrast angiography or echocardiography of the carotidarteries to rule out ischemic stroke associated with atherosclerotic plaque, arterialdissection, or other vascular diseases. (The aortic arch may also be evaluated byTEE).
- Hypercoagulable state assessment to rule out an underlying hypercoagulable state
Exclusion
Exclusion Criteria:
- Female participant who is pregnant, lactating or planning a pregnancy during thecourse of the study
- Age <18 or > 60 years of age
- Previous myocardial infarction or unstable angina within 6 months
- Clinically significant mitral or aortic valve stenosis or severe regurgitation
- Left Ventricular Ejection Fraction <50 percent
- Progressive neurological dysfunction or reduced life expectancy
- Contrast allergy
- Atrial Septal Defect (baseline left to right shunt assessed by TEE or other congenitalheart diseases
- Active Endocarditis
- Perspective participants with known causes of Ischemic Stroke
- Arterial dissection
- Contraindicated or unsuitable for antiplatelet agents or oral anticoagulants
- Perspective participants with prosthetic heart valves
- Uncontrolled diabetes Mellitus
- Pulmonary hypertension
- Uncontrolled systemic hypertension
- Intracranial pathology
- Neurological deficits not due to stroke that may affect neurologic assessments
- Active autoimmune disease
- Active infection
- Alcohol and/or drug abuse
- A requirement for chronic anticoagulation therapy that cannot be discontinued
- Anatomic features (inability to achieve vascular access)
Study Design
Total Participants: 640
Treatment Group(s): 2
Primary Treatment: Amplatzer PFO Occluder
Phase:
Study Start date:
January 01, 2021
Estimated Completion Date:
June 30, 2027
Study Description
Connect with a study center
Ospedale S. Eugenio
Roma, Lazio 00144
ItalySite Not Available
TMC HealthCare
Tucson, Arizona 85712
United StatesSite Not Available
Tampa General Hospital
Tampa, Florida 33606
United StatesActive - Recruiting
USF/Tampa General Hospital
Tampa, Florida 33606
United StatesSite Not Available
Lehigh Valley Health Network
Allentown, Pennsylvania 18103
United StatesSite Not Available
Inova Structural Heart Disease Program - Fairfax
Fairfax, Virginia 22042
United StatesSite Not Available
Inova Cardiovascular Institute
Falls Church, Virginia 22042
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.